Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response
Reads0
Chats0
TLDR
It is shown that α-Al(2)O(3) nanoparticles can act as an antigen carrier to reduce the amount of antigen required to activate T cells in vitro and in vivo.Abstract:
Therapeutic cancer vaccination is an attractive strategy because it induces T cells of the immune system to recognize and kill tumour cells in cancer patients. However, it remains difficult to generate large numbers of T cells that can recognize the antigens on cancer cells using conventional vaccine carrier systems. Here we show that α-Al(2)O(3) nanoparticles can act as an antigen carrier to reduce the amount of antigen required to activate T cells in vitro and in vivo. We found that α-Al(2)O(3) nanoparticles delivered antigens to autophagosomes in dendritic cells, which then presented the antigens to T cells through autophagy. Immunization of mice with α-Al(2)O(3) nanoparticles that are conjugated to either a model tumour antigen or autophagosomes derived from tumour cells resulted in tumour regression. These results suggest that α-Al(2)O(3) nanoparticles may be a promising adjuvant in the development of therapeutic cancer vaccines.read more
Citations
More filters
Journal ArticleDOI
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity
TL;DR: The significance of autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity as well as a growing body of literature suggesting that biopersistent nanom material can, in turn, negatively impact these pathways is highlighted.
Journal ArticleDOI
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp,Laura Senovilla,Ilio Vitale,Erika Vacchelli,Sandy Adjemian,Patrizia Agostinis,Lionel Apetoh,Fernando Aranda,Vincenzo Barnaba,Norma Bloy,Laura Bracci,Karine Breckpot,David Brough,Aitziber Buqué,Maria G. Castro,Mara Cirone,María Isabel Colombo,Isabelle Cremer,Sandra Demaria,Luciana Dini,Aristides G. Eliopoulos,Alberto Faggioni,Silvia C. Formenti,Jitka Fucikova,Lucia Gabriele,Udo S. Gaipl,Jérôme Galon,Abhishek D. Garg,François Ghiringhelli,Nathalia A. Giese,Zong Sheng Guo,Akseli Hemminki,Martin Herrmann,James W. Hodge,Stefan Holdenrieder,Jamie Honeychurch,Hong-Min Hu,Xing Huang,Timothy M Illidge,Koji Kono,Mladen Korbelik,Dmitri V. Krysko,Sherene Loi,Pedro R. Lowenstein,Enrico Lugli,Yuting Ma,Frank Madeo,Angelo A. Manfredi,Isabelle Martins,Domenico Mavilio,Laurie Menger,Nicolò Merendino,Michael Michaud,Grégoire Mignot,Karen L. Mossman,Gabriele Multhoff,Rudolf Oehler,Fabio Palombo,Theocharis Panaretakis,Jonathan Pol,Enrico Proietti,Jean-Ehrland Ricci,Chiara Riganti,Patrizia Rovere-Querini,Anna Rubartelli,Antonella Sistigu,Mark J. Smyth,Juergen Sonnemann,Radek Spisek,John Stagg,Abdul Qader Sukkurwala,Eric Tartour,Andrew Thorburn,Stephen H. Thorne,Peter Vandenabeele,Francesca Velotti,Samuel T Workenhe,Haining Yang,Wei-Xing Zong,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +81 more
TL;DR: Strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative I CD inducers are outlined, based on a high-content, high-throughput platform that was recently developed.
Journal ArticleDOI
Synthetic Nanoparticles for Vaccines and Immunotherapy
TL;DR: A review of nanoparticle-based strategies to immune modulation in detail, and discuss the promise and outstanding challenges facing the field of immune engineering from a chemical biology/materials engineering perspective can be found in this article.
Journal ArticleDOI
Engineering synthetic vaccines using cues from natural immunity
TL;DR: A rapidly growing field of research is the design of vaccines based on synthetic materials to target organs, tissues, cells or intracellular compartments; to co-deliver immunomodulatory signals that control the quality of the immune response; or to act directly as immune regulators.
Journal ArticleDOI
Engineering Nano‐ and Microparticles to Tune Immunity
TL;DR: Progress in the design of synthetic micro‐ and nano‐particles that can target drugs, deliver imaging agents, or stimulate immune cells directly through their physical and chemical properties is leading to new approaches to deliver vaccines, promote immune responses against tumors, and suppress autoimmunity.
References
More filters
Journal ArticleDOI
p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death
Geir Bjørkøy,Trond Lamark,Andreas Brech,Heidi Outzen,Maria Perander,Aud Øvervatn,Harald Stenmark,Terje Johansen +7 more
TL;DR: In this article, the polyubiquitin-binding protein p62/SQSTM1 has been shown to be involved in linking polyUBiquitinated protein aggregates to the autophagy machinery.
Journal ArticleDOI
Vaccine Adjuvants: Putting Innate Immunity to Work
TL;DR: There remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines, and the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens.
Journal ArticleDOI
A role for ubiquitin in selective autophagy.
TL;DR: The hypothesis that ubiquitin represents a selective degradation signal suitable for targeting various types of cargo, ranging from protein aggregates to membrane-bound organelles and microbes, is explored.
Journal ArticleDOI
Exploiting lymphatic transport and complement activation in nanoparticle vaccines.
Sai T. Reddy,André J. van der Vlies,Eleonora Simeoni,Veronique Angeli,Veronique Angeli,Gwendalyn J. Randolph,Conlin P. O'Neil,Leslie K. Lee,Melody A. Swartz,Jeffrey A. Hubbell +9 more
TL;DR: In this article, the authors investigate whether nanoparticles can be used as a vaccine platform by targeting lymph node-residing dendritic cells via interstitial flow and activating these cells by in situ complement activation.
Journal Article
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Sai T. Reddy,A. J. van der Vlies,Eleonora Simeoni,C. P. O"neil,Melody A. Swartz,Jeffrey A. Hubbell +5 more
TL;DR: This work investigates whether nanoparticles can be used as a vaccine platform by targeting lymph node–residing dendritic cells via interstitial flow and activating these cells by in situ complement activation, and demonstrates generation of humoral and cellular immunity in mice in a size- and complement-dependent manner.